This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.
The global market for antibody drug conjugates was valued at $179 million in 2012 and is estimated at $396 million for 2013. BCC Research projects the market to grow to nearly $2.8 billion by 2018, and register a five-year compound annual growth rate of 48.1% from 2013 to 2018.
Wellesley, MA (PRWEB) February 20, 2014
According to a new technical market research report Antibody Drug Conjugates: Technologies and Global Markets, from BCC Research (http://www.bccresearch.com), the global market for antibody drug conjugates was valued at $179 million in 2012 and is estimated at $396 million for 2013. BCC Research projects the market to grow to nearly $2.8 billion by 2018, and register a five-year compound annual growth rate of 48.1% from 2013 to 2018.
Antibody Drug Conjugates (ADCs), complex molecules composed of an antibody linked to a biological active cytotoxic drug, are a new class of biopharmaceutical drugs designed as a targeted therapy for the treatment of specific diseases such as cancer. Like any new subindustry, ADCs, as a group, are growing in part as the technological elements within the subindustry grow, expand and become refined. This growth requires significant research and development costs and time for development.
ADCs represent an overarching trend towards personalized and targeted therapy in medicine. As more gene- and protein-specific information is understood about disease, drugs are being designed to target these specific markers and to impact them in some way. As such, diagnostics are necessary to determine which patients should be put on these types of drugs. For example, Ventana Medical Systems has a strategic collaboration agreement with Bayer to develop a molecular companion diagnostic test intended to identify patients most likely to benefit from a novel Bayer ADC. Therefore, while only a fraction of patients with a disease will be appropriate for a particular ADC, the hope is that the targeted nature of the ADC will make it a more effective therapy for diseased tissue and spare healthy tissue from the medications effects.
To date, three ADC drugs, all anticancer focused, have become commercially approved by the United States Federal Drug Administration, as well as in other countries. Many more ADCs are in the pipeline and, as more is understood about the ADC paradigm, it is likely that other drugs will emerge that are focused not just on cancer but on other conditions as well. Intellect Neurosciences, for example, has an ADC-type of drug candidate that involves conjugating an antibody whose target is amyloid protein to help arrest Alzheimers disease.
Intense R&D spending, improved access to healthcare, and consumer demand will drive tremendous growth in this market for the foreseeable future.
This report provides a global overview of the global ADC market, including sales figures and projections out to 2018 including compound annual growth rates. In addition to looking at future and current markets for a wide variety of new, reformulated and established products, the study analyzes technological, environmental, legal/regulatory, and socioeconomic developments that may influence the market for ADC drugs. The study also presents an analysis of the emerging ADC industry and markets, geographically and by therapeutic area, including the relevant technology and where it fits into the pharmaceutical industry; key drivers and challenges; and important considerations including regulatory hurdles. It also provides analyses of commercialized ADCs and those in the development pipeline and development and alliance deals.
This report has been prepared for the entire pharmaceutical community. However, it is tailored especially for readers with an interest in the marketing, management, and public policy dimensions of ADC drugs, including readers in the following: pharmaceuticals industry, especially companies planning to enter this field; medial research institutions; international organizations and governmental organizations with relevant responsibilities such as health, drug safety, conservation and the environment, and foreign trade; investors; and the financial and analyst community.
For the original version on PRWeb visit: http://www.prweb.com/releases/2014/02/prweb11597603.htm
Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.